Aptevo Therapeutics (APVO) Operating Leases (2019 - 2025)
Aptevo Therapeutics (APVO) has disclosed Operating Leases for 7 consecutive years, with $4.0 million as the latest value for Q3 2025.
- Quarterly Operating Leases fell 16.67% to $4.0 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $4.0 million through Sep 2025, down 16.67% year-over-year, with the annual reading at $4.6 million for FY2024, 14.81% down from the prior year.
- Operating Leases hit $4.0 million in Q3 2025 for Aptevo Therapeutics, down from $4.2 million in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $6.4 million in Q2 2022 to a low of $1.1 million in Q1 2022.
- Historically, Operating Leases has averaged $4.3 million across 5 years, with a median of $4.8 million in 2024.
- Biggest five-year swings in Operating Leases: plummeted 48.09% in 2022 and later surged 436.36% in 2023.
- Year by year, Operating Leases stood at $1.3 million in 2021, then soared by 354.88% to $6.1 million in 2022, then fell by 11.48% to $5.4 million in 2023, then dropped by 14.81% to $4.6 million in 2024, then dropped by 13.04% to $4.0 million in 2025.
- Business Quant data shows Operating Leases for APVO at $4.0 million in Q3 2025, $4.2 million in Q2 2025, and $4.4 million in Q1 2025.